Cempra, Inc. to Present at Oppenheimer 23rd Annual Healthcare Conference
CHAPEL HILL, N.C., Dec. 5, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the Oppenheimer 23rd Annual Healthcare Conference at 11:10 a.m. EST, Wednesday, Dec. 12, at the Waldorf=Astoria in New York City. Dr. Fernandes will provide an update of the company's two leading antibiotic clinical programs, solithromycin (CEM-101) for community-acquired bacterial pneumonia and its fusidic acid (CEM-102) for the chronic, oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA) in prosthetic joint infections.
The presentation at the Oppenheimer 23rd Annual Healthcare Conference will be webcast live under the events section of Cempra's website at www.cempra.com and will be archived there following the presentation. Please connect to Cempra's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Cempra, Inc.
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates have both completed oral Phase 2 clinical trials and seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.
Investor and Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
Russo Partners, LLC
SOURCE Cempra, Inc.